Stefania Tacconelli, Melania Dovizio, Luigia Di Francesco, Alessandra Meneguzzi, Ilaria D'Agostino, Virgilio Evangelista, Stefano Manarini, Marta L Capone, Linda Grossi, Ettore Porreca, Concetta Di Febbo, Annalisa Bruno, Patrizia Ballerini, Giacomo Levantesi, Cristiano Fava, Pietro Minuz, Paola Patrignani
We studied the influence of cardiovascular(CV) risk factors, previous CV events, and co-treatments with preventive medicines, on residual platelet thromboxane(TX)B2 production in 182 patients chronically treated with enteric coated(EC)-aspirin(100mg/day). The response to aspirin was also verified by assessing arachidonic acid-induced platelet aggregation and urinary 11-dehydro-TXB2 levels. Residual serum TXB2 levels exceeded the upper limit value for an adequate aspirin response in 14% of individuals. This phenomenon was detected at 12h after dosing with aspirin...
March 25, 2018: Clinical Pharmacology and Therapeutics